MapLight Posts 97-Cent Quarterly Loss as Cash Burn Continues
MPLT sits 20% above its 52-week low of $6.06.
Summary
MapLight reported a third-quarter loss of 97 cents a share. That follows a Q2 loss of $60.2 million, disclosed in the 10-Q filed August 13, which came alongside a $150 million private placement the company said would fund operations through 2028. The company is a clinical-stage biotech with a market value around $400 million, so a quarterly loss of this size is a meaningful slice of its equity base and keeps the focus on how long the August cash lasts. The August PIPE also brought in Catalyst4, which bought $83.4 million of stock and warrants, and 13.2 million resale shares were registered in September, adding supply overhang. MapLight reports $463.4M in cash, with trial readouts expected in 2027–2028, and has sufficient funds to advance ML-007C-MA through 2028.
At the time of this announcement, MPLT was trading at $7.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $402.9M. The 52-week trading range was $6.06 to $40.43. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.